Understanding how cancer cells resist treatments that target autophagy
Resistance mechanisms to autophagy-modulating therapies
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11017826
This study is looking at how some cancer cells, especially in melanoma, become resistant to treatments that help them recycle and survive, and it aims to find better ways to combine these treatments with existing therapies to help patients respond better to their cancer care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11017826 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which cancer cells develop resistance to therapies that modulate autophagy, a process that helps cells recycle components and survive stress. By focusing on advanced cancer, particularly melanoma, the study aims to identify how certain proteins and pathways contribute to this resistance. The researchers will explore the effects of combining autophagy inhibitors with existing FDA-approved therapies to enhance treatment efficacy. Patients may be involved in clinical trials that test these new combinations to improve their response to cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced melanoma or other advanced cancers who have not responded to conventional treatments.
Not a fit: Patients with early-stage cancer or those who have not yet undergone any treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced cancer who currently do not respond to standard therapies.
How similar studies have performed: Other research has shown promising results in combining autophagy inhibitors with existing therapies, indicating potential for success in this approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AMARAVADI, RAVI K — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: AMARAVADI, RAVI K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, anti-cancer therapy